Article Versions Notes

Tamalunas A, Aydogdu C, Unterrainer LM, Schott M, Rodler S, Ledderose S, Schulz GB, Stief CG, Casuscelli J. The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder. Cancers. 2024; 16(8):1536. https://doi.org/10.3390/cancers16081536

Tamalunas, Alexander, Can Aydogdu, Lena M. Unterrainer, Melanie Schott, Severin Rodler, Stephan Ledderose, Gerald B. Schulz, Christian G. Stief, and Jozefina Casuscelli. 2024. "The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder" Cancers 16, no. 8: 1536. https://doi.org/10.3390/cancers16081536

Tamalunas, A., Aydogdu, C., Unterrainer, L. M., Schott, M., Rodler, S., Ledderose, S., Schulz, G. B., Stief, C. G., & Casuscelli, J. (2024). The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder. Cancers, 16(8), 1536. https://doi.org/10.3390/cancers16081536